Good MorningEquity markets rebounded on Wednesday to add about 1.5% to the S&P 500. The driver was better than expected earnings from Nike that have enriched hopes that Q4 earnings reporting season won't be as bad as feared. As it is, the market is expecting about a 2.5% decline in S&P 500 earnings and the consensus is falling. The takeaway for investors is that results may be enough to keep the bulls interested and the S&P 500 bobbing sideways within its current range.
The big news this week will come out tomorrow with the PCE price index. The index is expected to subside on a YOY basis at the core level which is what the market needs to see. If the index confirms expectations there is a very good chance Santa Clause will bring a rally next week. Featured: Sell these "safe" blue chips immediately (Ad) 
|
Markets | |
What is dividend yield? It’s an excellent question for budding investors.
Dividends are one of only two reasons to own stocks and the only reason you can rely on stock to any extent. Dividends are the payments publicly traded companies pay to their investors, and the dividend yield measure... Read the Full Story |
|
From Our Partners | | Porter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down year in nearly two decades and total gains of almost 2,000% - his immediate reaction was disbelief.
It took a trusted friend's personal vouching for Emmet Savage and a face-to-face trip to Ireland to change his mind. The full documentary, Investigating Project Prophet, is now live. | | Watch the full story and see the verified track record for yourself |
|
Technology | |
As temperatures drop throughout the U.S., sunshine and warmth may seem like distant dreams. But for shareholders of top-performing solar-energy stocks such as Enphase Energy Inc. (NASDAQ: ENPH), SolarEdge Technologies Inc. (NASDAQ: SEDG), and First Solar Inc. (NASDAQ: FSLR), those brighter days ma... Read the Full Story |
|
Consumer Discretionary | |
On a day when the broader market soared over 500 points, Lucid Group, Inc. (NASDAQ: LCID) was a notable laggard. Shares of LCID stock fell by less than one percent. But it continues the downward trend for the stock, down 30% in the last month and over 80% in 2022.
One sore spot for investors is ... Read the Full Story |
|
From Our Partners | | Moderna's stock doubled in a single day after its cancer vaccine hit key Phase 3 goals, and Merck jumped too. But according to a former Steve Cohen fund manager, the next big opportunity is not Moderna or Merck.
It is a different kind of company tied to a technology already backed by Elon Musk, Sam Altman, Jeff Bezos, and Peter Thiel. Nvidia's Jensen Huang says it will have a dramatic impact on daily life, while Anthropic's CEO believes it could unlock a century of medical progress in just ten years.
Nature Magazine estimates its potential value at $367 trillion globally, and it is already rolling out across the United States. | | Click here to learn about this new era of medical technology |
|
Markets | |
The institutions have helped to indicate a bottom in Rite Aid Corporation (NYSE: RAD) shares, not so much because of their buying but the opposite. The institutions had been heavy buyers all year despite the downturn in the price action, but that changed in Q4. In Q4 a broad array of sell-side ins... Read the Full Story |
|
Industrials | |
Shares of Fedex Corporation (NYSE: FDX) are up over 5% the day after the company surprised investors with a beat on the bottom line. The $3.18 earnings per share (EPS) the company delivered was over 12% higher than analysts’ expectations for EPS of $2.82.
That’s the good news. The ba... Read the Full Story |
|
From Our Partners | | Gold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying out up to $1,152 a month to regular investors - no mining stocks, no options, no physical metal required.
Chief Income Strategist Tim Plaehn calls it a breakthrough strategy that transforms gold's rally into reliable monthly payouts. The next distribution is just days away. | | Discover the gold income fund before the next payout date |
|
Healthcare | |
Viking Therapeutics (NASDAQ: VKTX) develops novel therapeutics for patients suffering from disorders related to the metabolic and endocrine systems. Recently, their stock soared for a somewhat unique reason: the success of a peer. While they can certainly develop their own promising products, thei... Read the Full Story |
|
Consumer Discretionary | |
NIKE, Inc. (NYSE: NKE) stock is set up for a reversal, and the 2023 outlook may drive it. The company just reported earnings for CQ4 and not only beat on the top and bottom lines but showed significant improvement in its inventory position. This is important because bloating inventories and the ne... Read the Full Story |
|
Communication Services | |
The ongoing saga of meme stock AMC Entertainment Holdings Inc (NYSE: AMC) has captivated traders for the past two years. But its fortunes are linked to those of other companies, such as little-known real estate investment trust EPR Properties (NYSE: EPR).
AMC shares are down 82% in 2022.
AMC h... Read the Full Story |
|
Consumer Discretionary | |
Consumer staples giant Kellogg Company (NYSE: K) stock is having a great year, trading up +12% versus the S&P 500 (NYSEARCA: SPY) , which is trading down (-20%) for 2022. The high inflation and an uncertain economic climate have benefited consumer staples companies. Kellogg is well known for i... Read the Full Story |
|
Consumer Staples | |
General Mills (NYSE: GIS) has been advancing on solid performance driven by its Accelerate strategy. The strategy is focused on brand innovation, portfolio strength and operational capabilities, and it is paying off. The FQ2/CQ4 results prove that not only is the company able to grow in adverse co... Read the Full Story |
|
Thursday's Early Bird Stock Of The Day Portage Biotech Inc., a clinical stage immune-oncology company, engages in the research and develops pharmaceutical and biotechnology products. Its product pipeline includes PORT-2 for treatment of refractory NSCLC, melanoma, and refractory melanoma that is in phase I and phase II clinical trials; PORT-3, for treatment of solid tumors, which is in phase I clinical trials; PORT-6, an A2AR inhibitor to treat A2A & A2B high solid tumors that is in phase Ia clinical trials; PORT-7, an A2AR inhibitor to treat A2A & A2B high solid tumors that is in phase Ib clinical trials; PORT-1, an intratumoral amphiphilic solutions for treatment of advanced soft tissue sarcoma, which is in phase 3 clinical trials; PORT-4, a nanolipogel co-formulations to treat of solid tumors that is in preclinical trials; and PORT-5, a VLP-STING to treat of solid tumors that is in preclinical trials. The company is based in Tortola, British Virgin Islands. | | View Today's Stock Pick |
|
